Fri, Feb 27, 2015, 8:20 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • opinionscincy opinionscincy Feb 21, 2012 5:41 PM Flag


    Following the US Food and Drug Administration (:FDA) approval for the said indication, Merck KGaA will initially be responsible for the commercialization of TH-302, while Threshold Pharma will receive tiered, double-digit royalty on sales. As a part of the agreement, Threshold Pharma will have the option to co-promote the candidate in the US.

    Outside the US, Merck KGaA will be solely responsible for the commercialization of TH-302 and Threshold Pharma will receive tiered, double-digit royalty on sales in these territories.

    Merck KGaA and Threshold Pharma will jointly develop TH-302 for all other cancer indications.

    Under the deal, Threshold Pharma will receive an upfront payment of €19 million ($25 million) and is eligible to receive up to €26.5 million ($35 million) as development milestone payments during 2012. Threshold Pharma can also receive a €15 million ($20 million) milestone payment if the candidate delivers positive phase II results in pancreatic cancer. Further, Merck KGaA will pay 70% of worldwide development costs for TH-302.

    We believe this agreement is a positive development for the company as it will help expand Merck KGaA’s oncology portfolio.

4.37-0.06(-1.35%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.